Quadrature Capital Ltd Purchases Shares of 532,436 Bristol Myers Squibb Company $BMY

Quadrature Capital Ltd purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 532,436 shares of the biopharmaceutical company’s stock, valued at approximately $24,008,000.

A number of other institutional investors have also modified their holdings of BMY. Vanguard Group Inc. boosted its stake in shares of Bristol Myers Squibb by 0.5% in the third quarter. Vanguard Group Inc. now owns 195,984,009 shares of the biopharmaceutical company’s stock worth $8,838,879,000 after buying an additional 1,058,803 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Bristol Myers Squibb by 16.8% during the second quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock valued at $3,277,456,000 after acquiring an additional 10,195,775 shares in the last quarter. Norges Bank acquired a new position in Bristol Myers Squibb in the second quarter valued at approximately $1,554,154,000. Ameriprise Financial Inc. lifted its holdings in Bristol Myers Squibb by 1.3% in the second quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock valued at $1,508,099,000 after acquiring an additional 432,158 shares during the period. Finally, Independent Franchise Partners LLP boosted its position in Bristol Myers Squibb by 20.6% in the 2nd quarter. Independent Franchise Partners LLP now owns 20,976,954 shares of the biopharmaceutical company’s stock worth $971,023,000 after purchasing an additional 3,583,163 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $58.93 on Friday. The stock has a market capitalization of $120.00 billion, a P/E ratio of 17.08, a P/E/G ratio of 0.17 and a beta of 0.26. The company’s fifty day moving average price is $58.12 and its 200 day moving average price is $51.32. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business’s revenue was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Analysts Set New Price Targets

BMY has been the subject of several recent research reports. Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and lifted their target price for the company from $52.00 to $61.00 in a report on Monday, December 15th. Leerink Partners increased their price target on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Guggenheim restated a “buy” rating and set a $72.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Scotiabank reaffirmed a “sector perform” rating and issued a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $57.00 target price (up from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. Nine investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $61.00.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.